Who owns Artiva Biotherapeutics, Inc. (ARTV)? Elite investor 13F holders
3 tracked elite investors reported holding Artiva Biotherapeutics, Inc as of 2026-06-30, including Viking Global Investors, Caligan Partners, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Viking Global Investors | ARTIVA BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 25260410.00 USD | 2604166.000000 | Shares | buy | Original filing |
| Caligan Partners | ARTIVA BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 16840277.00 USD | 1736111.000000 | Shares | buy | Original filing |
| Renaissance Technologies LLC | ARTIVA BIOTHERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1464700.00 USD | 151000.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.